{rfName}
Mu

Indexed in

License and use

Citations

191

Altmetrics

Grant support

This research was supported in part by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH. S.K.D., L.C.S., and the Myositis Research Database are supported by the Huayi and Siuling Zhang Discovery Fund. I.P.-F.'s research is supported by a Fellowship from the Myositis Association. J.J.P. is supported by the Doris Duke Early Investigator Award. E.T. is supported by grants from the Rheumatology Research Foundation and the Jerome L. Greene Foundation.

Analysis of institutional authors

Milisenda, JoseAuthor
Share
Publications
>
Article

Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies

Publicated to:Neurology. 90 (23): E2068-E2076 - 2018-06-05 90(23), DOI: 10.1212/WNL.0000000000005638

Authors: De Lorenzo, Rebecca; Pinal-Fernandez, Iago; Huang, Wilson; Albayda, Jemima; Tiniakou, Eleni; Johnson, Cheilonda; Milisenda, Jose C; Casal-Dominguez, Maria; Corse, Andrea M; Danoff, Sonye K; Christopher-Stine, Lisa; Paik, Julie J; Mammen, Andrew L

Affiliations

and Johns Hopkins University School of Medicine (I.P.-F., J.A., E.T., C.J., M.C.-D., A.M.C., S.K.D., L.C.-S., J.J.P., A.L.M.), Baltimore, MD. - Author
and Johns Hopkins University School of Medicine (I.P.-F., J.A., E.T., C.J., M.C.-D., A.M.C., S.K.D., L.C.-S., J.J.P., A.L.M.), Baltimore, MD. andrew.mammen@nih.gov jpaik1@jhmi.edu. - Author
From the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R.D.L., I.P.-F., W.H., J.C.M., M.C.-D., A.L.M.), NIH, Bethesda - Author
Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA - Author
NIAMSD, NIH, Bethesda, MD 20892 USA - Author
See more

Abstract

To define the clinical features of myositis patients with anti-PM/Scl-75 and/or anti-PM/Scl-100 autoantibodies at disease onset and during the course of disease and compare them to patients with other forms of myositis.In this longitudinal cohort study, the prevalence and severity of clinical features at disease onset and during follow-up were compared between anti-PM/Scl-positive patients and those with the antisynthetase syndrome (AS), dermatomyositis (DM), and immune-mediated necrotizing myopathy (IMNM).Forty-one anti-PM/Scl-positive, 132 AS, 178 DM, and 135 IMNM patients were included. Although muscle weakness was a presenting feature in just 37% of anti-PM/Scl-positive patients, 93% eventually developed weakness. Unlike the other groups, anti-PM-Scl-positive patients had more severe weakness in arm abductors than hip flexors. Interstitial lung disease was a presenting feature in just 10% of anti-PM/Scl-positive patients, but occurred in 61% during follow-up; fewer patients with DM (13%, p < 0.001) and IMNM (6%, p < 0.001) and more patients with AS (80%, p < 0.05) developed interstitial lung disease during the course of disease. Mechanic's hands (80%), Raynaud syndrome (78%), sclerodactyly (66%), telangiectasias (66%), esophageal reflux disease (61%), subcutaneous edema (46%), puffy hands (39%), and calcinosis (39%) occurred more frequently in anti-PM/Scl-positive patients than in the other groups. Although 30% of anti-PM/Scl-positive patients met criteria for systemic sclerosis, less than 5% had renal crisis or finger ulcerations. No differences were found between patients with only anti-PM/Scl-100 or only anti-PM/Scl-75 autoantibodies.Unlike patients with DM, AS, or IMNM, anti-PM/Scl-positive patients have weaker arm abductors than hip flexors. Anti-PM/Scl-positive patients also have the most extensive extramuscular features.© 2018 American Academy of Neurology.

Keywords
antibodiesclassificationdermatomyositisdiseasemyositis-specific autoantibodiesoverlap syndromespm-sclrheumatoid-arthritissystemic-sclerosisAntibodiesClassificationDermatomyositisDiseaseIdiopathic inflammatory myopathyMyositis-specific autoantibodiesOverlap syndromesPm-sclRheumatoid-arthritisSystemic-sclerosis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Neurology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2018, it was in position 10/199, thus managing to position itself as a Q1 (Primer Cuartil), in the category Clinical Neurology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.98. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 3.35 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 24.42 (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-13, the following number of citations:

  • WoS: 76
  • Scopus: 86
  • Europe PMC: 29
  • OpenCitations: 81
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-13:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 67.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 67 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 10.35.
  • The number of mentions on the social network X (formerly Twitter): 12 (Altmetric).
Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Timor-Leste; United States of America.